Bora Pharmaceuticals, a Taipei City, Taiwan-based pharmaceutical company and CDMO of drug products, has agreed to acquire Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland. This announcement comes after Emergent BioSolutions’ recently announced a restructuring plan. 

Last month (May 2024), Emergent BioSolutions’ announced the next phase of a new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its workforce. As part of its operational changes, Emergent will shut down both its Baltimore-Bayview, drug-substance manufacturing facility and Rockville, Maryland, drug-product facility. Emergent will concentrate operations at sites in Winnipeg, Canada, and Lansing, Michigan, while the company explores strategic alternatives for its other sites throughout the year (2024).  

Bora’s newly acquired 87,000-square-foot facility provides drug-product manufacturing services for sterile injectables and clinical and commercial non-viral aseptic fill-finish services on four fill lines, including lyophilization, vials filling, and pre-filled syringe filling.  

Source: Bora Pharmaceuticals